[CNCE] Concert Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 10.1 Change: 0.56 (5.87%)
Ext. hours: Change: 0 (0%)

chart CNCE

Refresh chart

Strongest Trends Summary For CNCE

CNCE is in the medium-term down -47% below S&P in 5 months and down -64% below S&P in 1 year. In the long-term down -76% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, renal disease, inflammation, and cancer. The company?s clinical-stage product candidates include CTP-354, which in Phase I clinical trial for spasticity associated with multiple sclerosis and spinal cord injury; CTP-499 that is in Phase II clinical trial for diabetic kidney disease; and AVP-786 for neurologic and psychiatric disorders. Its preclinical compounds comprise CTP-730 for inflammatory diseases; JZP-386, a deuterated analog of sodium oxybate for narcolepsy; and C-10068, an oral deuterium-substituted analog of dextroethorphan, which is used for the treatment of pain and seizure-generating diseases and injuries, such as epilepsy, ischemic stroke, and traumatic brain injury. The company has collaborations with Avanir Pharmaceuticals, Inc., Celgene Corporation, Celgene International Sàrl, and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. w

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.75% Sales Growth - Q/Q-0.31% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.52% ROE-36.1% ROI
Current Ratio7.95 Quick Ratio Long Term Debt/Equity Debt Ratio0.16
Gross Margin Operating Margin-398.48% Net Profit Margin-408.16% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities45.18 M Cash From Investing Activities16.27 M Cash From Operating Activities-11.04 M Gross Profit
Net Profit-9 M Operating Profit-8.87 M Total Assets118.36 M Total Current Assets115.64 M
Total Current Liabilities14.55 M Total Debt5.04 M Total Liabilities24.87 M Total Revenue1.31 M
Technical Data
High 52 week17.54 Low 52 week5.71 Last close6.21 Last change5.43%
RSI13.12 Average true range0.71 Beta1.16 Volume93.53 K
Simple moving average 20 days-18% Simple moving average 50 days-33.51% Simple moving average 200 days-46.86%
Performance Data
Performance Week6.7% Performance Month-43.18% Performance Quart-44.65% Performance Half-37.96%
Performance Year-61.97% Performance Year-to-date-55.45% Volatility daily9.96% Volatility weekly22.28%
Volatility monthly45.66% Volatility yearly158.19% Relative Volume180.54% Average Volume218.05 K
New High New Low

News

2019-12-02 07:00:00 | Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia

2019-11-15 19:31:18 | Edited Transcript of CNCE earnings conference call or presentation 7-Nov-19 1:30pm GMT

2019-11-12 07:00:00 | Concert Pharmaceuticals to Present at Upcoming Investor Conferences

2019-11-10 08:40:05 | Should You Worry About Concert Pharmaceuticals, Inc.'s NASDAQ:CNCE CEO Salary Level?

2019-11-07 08:15:01 | Concert Pharmaceuticals CNCE Reports Q3 Loss, Misses Revenue Estimates

2019-11-07 07:00:00 | Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update

2019-11-06 07:00:00 | Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia

2019-11-05 13:36:25 | Concert Pharmaceuticals Inc CNCE Is Burning These Hedge Funds

2019-10-31 10:35:02 | Analysts Estimate Concert Pharmaceuticals CNCE to Report a Decline in Earnings: What to Look Out for

2019-10-31 07:00:00 | Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019

2019-10-12 03:15:00 | Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress

2019-10-02 07:00:00 | Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference

2019-09-27 11:48:22 | Concert stock falls 36 percent on Alzheimer's drug trial failure

2019-09-23 07:00:00 | Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer

2019-09-19 10:32:20 | Did You Manage To Avoid Concert Pharmaceuticals's NASDAQ:CNCE 20% Share Price Drop?

2019-09-17 07:00:00 | Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata

2019-09-12 07:00:00 | Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

2019-08-29 07:00:00 | Concert Pharmaceuticals to Present at Upcoming Investor Conferences

2019-08-16 15:10:37 | What You Must Know About Concert Pharmaceuticals, Inc.'s NASDAQ:CNCE Beta Value

2019-08-06 05:12:22 | Concert Pharmaceuticals, Inc. CNCE Q2 2019 Earnings Call Transcript

2019-08-03 17:03:06 | Edited Transcript of CNCE earnings conference call or presentation 1-Aug-19 12:30pm GMT

2019-08-01 09:25:01 | Concert Pharmaceuticals CNCE Reports Q2 Loss, Misses Revenue Estimates

2019-07-25 07:00:00 | Concert Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 1, 2019

2019-07-05 15:12:37 | Concert Pharmaceuticals, Inc. NASDAQ:CNCE Insiders Increased Their Holdings

2019-06-13 17:05:09 | Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I

2019-06-12 07:00:00 | Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers

2019-06-05 07:00:00 | Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

2019-05-16 07:00:00 | Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

2019-05-14 07:00:00 | Concert Pharmaceuticals to Present at Upcoming Investor Conferences

2019-05-07 13:51:01 | Why Concert Pharmaceuticals, Inc.'s NASDAQ:CNCE CEO Pay Matters To You

2019-05-02 17:39:28 | Edited Transcript of CNCE earnings conference call or presentation 2-May-19 12:30pm GMT

2019-05-02 11:52:23 | Concert Pharmaceuticals, Inc. CNCE Q1 2019 Earnings Call Transcript

2019-05-02 08:01:44 | Concert: 1Q Earnings Snapshot

2019-05-02 07:00:00 | Concert Pharmaceuticals Reports First Quarter 2019 Financial Results

2019-04-29 07:00:00 | Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors

2019-04-25 10:34:02 | Earnings Preview: Concert Pharmaceuticals CNCE Q1 Earnings Expected to Decline

2019-04-25 07:00:00 | Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019

2019-04-11 09:46:01 | Concert Pharma Initiates Early-Stage Schizophrenia Study

2019-04-11 07:00:00 | Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting

2019-04-10 06:30:00 | Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

2019-04-08 15:09:00 | Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling

2019-04-08 14:45:00 | Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding

2019-03-25 10:42:02 | New Strong Sell Stocks for March 25th

2019-03-12 08:13:12 | New Strong Sell Stocks for March 12th

2019-03-12 07:00:00 | Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference

2019-03-07 08:40:01 | Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

2019-03-06 07:00:00 | Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

2019-03-01 07:00:00 | Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting

2019-03-01 06:40:22 | Edited Transcript of CNCE earnings conference call or presentation 28-Feb-19 1:30pm GMT

2019-02-28 10:49:19 | Concert Pharmaceuticals, Inc. CNCE Q4 2018 Earnings Conference Call Transcript